Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate.
This is the first patient report of maternal ingestion of anticonvulsants associated with the triad of fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease. The neuroblastoma, a neural crest tumor, is the fourth of such origin reported after in utero exposure to phenytoin, suggesting that phenytoin is a transplacental carcinogen. Infants of epileptic mothers receiving anticonvulsants should be closely examined at birth for the fetal hydantoin syndrome and monitored for hemorrhagic problems. The neural crest tumor may be found at birth or later in childhood.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000015:Abnormalities, Multiple / Q000139:chemically induced*; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000378:metabolism; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D009447:Neuroblastoma / Q000139:chemically induced*; D010672:Phenytoin / Q000009:adverse effects*; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013577:Syndrome; D006475:Vitamin K Deficiency Bleeding / Q000139:chemically induced*
D006827:Hydantoins; D010672:Phenytoin